Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Genitourinary System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm

Cancer Family

Genitourinary System Neoplasm

CI-CAN-00000018Explore in graph →

Non-malignant3,849 active trials61 approved drugs306 evidence items

NCIt: C156482

Overview
Statistics
Survival
Genomics114
Variants & evidence306
Drugs75
Trials17388
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (892)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 776–800 of 892 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

BCOR-CCNB3 fusion-positive clear cell sarcoma of the kidney.
· Pediatr Blood Cancer · 2020 · PMID 31876361 · validated civic_curation pubmed
Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues.
· Am J Surg Pathol · 2017 · PMID 28817404 · validated civic_curation pubmed
Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.
· J Pathol · 2014 · PMID 25111426 · validated civic_curation pubmed
Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC.
· Hum Mutat · 1999 · PMID 10408776 · validated civic_curation pubmed
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.
· Cancer Res · 1994 · PMID 8187067 · validated civic_curation pubmed
Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.
· BMC Cancer · 2005 · PMID 15932632 · validated civic_curation pubmed
VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium.
· Oncogene · 2001 · PMID 11536052 · validated

Showing 776–800 of 892 publications

← Previous
1
…
31
32
33
…
36
Next →

civic_curation

Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers.

· Int J Cancer · 1995 · PMID 7591282 · validated civic_curation pubmed

Mutations of the VHL tumour suppressor gene in renal carcinoma.

· Nat Genet · 1994 · PMID 7915601 · validated civic_curation pubmed

[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].

· Hinyokika Kiyo · 2013 · PMID 23995526 · validated civic_curation pubmed

EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.

· Front Med (Lausanne) · 2022 · PMID 35572973 · validated civic_curation pubmed

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.

· Eur J Hum Genet · 2002 · PMID 12461689 · validated civic_curation pubmed

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

· Cancer Discov · 2013 · PMID 23779130 · validated civic_curation pubmed

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

· Cancer Res · 2003 · PMID 12517791 · validated civic_curation pubmed

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

· Proc Natl Acad Sci U S A · 2001 · PMID 11504908 · validated civic_curation pubmed

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

· Cancer Res · 2014 · PMID 24240700 · validated civic_curation pubmed

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.

· Br J Cancer · 2014 · PMID 25010864 · validated civic_curation pubmed

Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.

· Carcinogenesis · 2013 · PMID 23764753 · validated civic_curation pubmed

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

· Clin Cancer Res · 2017 · PMID 27663592 · validated civic_curation pubmed

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

· Carcinogenesis · 2006 · PMID 16338952 · validated civic_curation pubmed

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

· Cancer Res · 2009 · PMID 19244107 · validated civic_curation pubmed

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

· Cancer Res · 2009 · PMID 19117982 · validated civic_curation pubmed

Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.

· J Clin Invest · 2024 · PMID 38687617 · validated civic_curation pubmed

Identification of targetable FGFR gene fusions in diverse cancers.

· Cancer Discov · 2013 · PMID 23558953 · validated civic_curation pubmed

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

· Cancer Cell · 2015 · PMID 25670080 · validated civic_curation pubmed